
Minutes of Meeting, March 23, 2011 - Spherusol

 

 
Meeting ID#:                       BLA 125354

                                               

Product Name:                    Coccidioides immitis Spherule-Derived Skin Test Antigen

 

Sponsor:                             Allermed Laboratories, Inc.

 

Sponsor Contact:                 H.S. Nielsen, Jr., Ph.D.

                                                               

Meeting Type:                      Internal

 

Meeting Date/Time:             March 23, 2011, 3:30 PM

 

Meeting Format:                  WOC 2 CR 2330 with Teleconferencing available

 

Meeting Chair/Leader:         Sheldon Morris, Chair

 

Meeting Recorder:                Holly Wieland

 

CBER Attendees:                      Jennifer Bridgewater

  Karen Campbell

  Dennis Cato

  Siobhan Cowley

  Jon Daugherty

  Karen Elkins

  Doran Fink

  Amelia Horne                         

  Anthony Hawkins

  Dana Jones

  Jingyee Kou

  Sheldon Morris

  Alexis Mosquera

  Douglas Pratt

  Paul Richman

  Jeff Roberts

  Estelle Russek-Cohen

  Ann Schwartz

  Wellington Sun

  Joseph Temenak

  Deborah Trout

  Holly Wieland

  Craig Zinderman

 

Brief Background/Development Plan 

 

In the submission dated January 17, 2011, in response to the Type B Meeting held on January 12, 2011, the sponsor has submitted the proposed indication for this product:

 

"Spherusol is indicated for use as a skin test antigen for the detection of delayed type (IV) cell mediated hypersensitivity following pulmonary infection with C. immitis.”

 

"Spherusol should not be used to diagnose active disease or disseminated disease caused by C. immitis because it has not been studied for use in diagnosing those conditions."

 

Purpose of Meeting 



The purpose of this meeting is to come to final agreement on the following:

 

1. Assuming there are no other review issues, can this product be licensed without any further clinical studies?

 

2. If the answer is 'yes', what will be the specific indication?

 

3. If additional clinical studies are needed, will they need to be conducted pre-licensure or post-licensure?

 

Meeting Discussion



The following points were discussed during the meeting.

 

1. CBER may allow a very narrow indication limiting it to what the sponsor evaluated, that is:

a. In the endemic area, people with a known history of disease tested positive;

b. In a non-endemic area, people with no known history of disease tested negative;

c. In a non-endemic area, testing for cross-reactivity in individuals with histoplasmosis was negative.

 

2. This product has not been tested on any special populations, such as pregnant women or immunocompromised people. The sponsor will need to do additional clinical trials before those indications could be considered.

 

3. This action should not be viewed as setting precedent. Rather, one could view this as a special case because ------------------------------------(b)(4)----------------------------------------

 

Action Items 



The review team will continue to work on the language for the indication. The proposed indication and other labeling as it relates to the proposed indication will be addressed in the labeling review and negotiations. Consensus is building that the sponsor may be allowed a very narrow indication such as follows:

 

Spherusol is a skin test antigen indicated for the detection of delayed type hypersensitivity to C. immitis in healthy individuals with a past history of pulmonary coccidioidomycosis.

 

Spherusol should not be used to diagnose active disease or disseminated disease caused by C. immitis.

 

 

Committee members were requested to prepare to complete the action on this BLA at least 2 to 3 weeks prior to the action due date of July 29, 2011.